After TAVI, anticoagulants outperform antiplatelet agents at preventing clots

After transcatheter aortic valve implantation (TAVI), anticoagulation reduced imaging signs of clot formation on the new valve compared with antiplatelet therapy, without compromising safety. This was the main finding of the ACASA-TAVI trial presented in a Hot Line session at ESC Congress 2026 and published simultaneously in JAMA.

≈